statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	848
DE - Germania	229
SG - Singapore	141
CN - Cina	133
SE - Svezia	74
BR - Brasile	54
UA - Ucraina	47
FR - Francia	43
VN - Vietnam	31
IT - Italia	18
IN - India	17
IE - Irlanda	16
FI - Finlandia	10
ID - Indonesia	10
BD - Bangladesh	9
JP - Giappone	9
GB - Regno Unito	7
MX - Messico	6
PK - Pakistan	6
RU - Federazione Russa	5
AE - Emirati Arabi Uniti	4
BE - Belgio	4
CA - Canada	4
IQ - Iraq	4
NL - Olanda	4
TR - Turchia	4
ZA - Sudafrica	4
AR - Argentina	3
AT - Austria	3
EC - Ecuador	3
HK - Hong Kong	3
KR - Corea	3
BB - Barbados	2
CO - Colombia	2
CZ - Repubblica Ceca	2
ES - Italia	2
ET - Etiopia	2
JO - Giordania	2
MA - Marocco	2
PL - Polonia	2
PY - Paraguay	2
BG - Bulgaria	1
CH - Svizzera	1
CL - Cile	1
DZ - Algeria	1
FJ - Figi	1
HN - Honduras	1
HR - Croazia	1
IL - Israele	1
IR - Iran	1
IS - Islanda	1
JM - Giamaica	1
KE - Kenya	1
LA - Repubblica Popolare Democratica del Laos	1
MR - Mauritania	1
NI - Nicaragua	1
NO - Norvegia	1
PS - Palestinian Territory	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
UY - Uruguay	1
VE - Venezuela	1
Totale	1.796

Nome	#
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature	430
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes.	192
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.	192
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms	180
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms	171
Similarities and differences between therapy-related and elderly acute myeloid leukemia	170
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes	169
PU.1 and CEBPA expression in acute myeloid leukemia.	153
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine	149
Totale	1.806

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	22	0	0	0	0	0	0	0	0	0	0	21	1
2021/2022	73	17	10	1	2	5	2	1	13	3	3	8	8
2022/2023	193	18	28	19	37	12	27	9	15	21	1	4	2
2023/2024	80	5	19	4	1	6	22	2	0	0	0	14	7
2024/2025	418	4	4	13	6	16	2	3	14	33	14	287	22
2025/2026	451	76	13	23	40	72	44	73	23	40	45	2	0
Totale													1.806

IRIS UniCatt